DTDébora Broch Trentini

Débora Broch Trentini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Débora Broch Trentini has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Tom Eisenack

    University of Cologne, Faculty of Medicine, University Hospital of Cologne, Center for Molecular Medicine Cologne (CMMC), Cologne, Germany

    3 shared publications
  • Raquel Gonçalves Torres

    University of Cologne, Faculty of Medicine, University Hospital of Cologne, Center for Molecular Medicine Cologne (CMMC), Cologne, Germany

    2 shared publications
  • Robin Renn

    University of Cologne, Faculty of Medicine, University Hospital of Cologne, Center for Molecular Medicine Cologne (CMMC), Cologne, Germany

    2 shared publications
  • Romy Enrica Baier

    University of Cologne, Faculty of Medicine, University Hospital of Cologne, Center for Molecular Medicine Cologne (CMMC), Cologne, Germany

    2 shared publications
  • Alain Lilienbaum

    Basic and Translational Myology, Unit of Functional and Adaptive Biology, Universite Paris Cite / CNRS UMR 8251, Paris, France

    1 shared publication
  • Ana Ferreiro

    Basic and Translational Myology, Unit of Functional and Adaptive Biology, Universite Paris Cite / CNRS UMR 8251, and Reference Center for Neuromuscular Disorders, Pitie-Salpetriere Hospital, AP-HP, Paris, France

    1 shared publication

Latest Publications

  • Open Access

    Principles of ribosome-associated protein quality control during the synthesis of CFTR

    by Tom Joshua Oldfield, Raquel Gonçalves Torres, Romy Enrica Baier, Robin Renn, Débora Broch Trentini

    Prolonged translational arrests caused by defective mRNAs activate the ribosome-associated protein quality control (RQC) pathway, which marks harmful incomplete proteins for degradation. Multipass transmembrane proteins have increased propensity to be targeted by the RQC, raising the question of whether problems in transmembrane domain insertion and assembly can also cause RQC-eliciting translational arrests. Here, we investigated RQC-mediated quality control of CFTR, a large transmembrane protein mutated in cystic fibrosis. Reporter assays showed that although a fraction of nascent CFTR expressed in HEK293 cells arrested during translation and activated the RQC, multiple interventions compromising CFTR folding and membrane insertion did not exacerbate this response. CFTR translation abortion was also largely unaffected by regulators of translation kinetics such as codon usage, the ribosome collision sensor GCN1, and the SRP ER targeting complex. We propose that the RQC can be triggered by the inherent difficulties in synthesizing transmembrane segments, resulting from their inappropriate interaction with the protein synthesis machinery. Our study uncovers and characterizes a novel physiological role for the RQC in dealing with elongation-arrested transmembrane proteins.

  • Open Access

    Principles of ribosome-associated protein quality control during the synthesis of CFTR

    by Tom Joshua Oldfield, Raquel Gonçalves Torres, Romy Enrica Baier, Robin Renn, Débora Broch Trentini

    Prolonged translational arrests caused by defective mRNAs activate the ribosome-associated protein quality control (RQC) pathway, which marks harmful incomplete proteins for degradation. Multipass transmembrane proteins have increased propensity to be targeted by the RQC, raising the question of whether problems in transmembrane domain insertion and assembly can also cause RQC-eliciting translational arrests. Here, we investigate RQC-mediated quality control of CFTR, a large transmembrane protein mutated in cystic fibrosis. Reporter assays show that although a fraction of nascent CFTR expressed in HEK293 cells arrests during translation and activates the RQC, multiple interventions compromising CFTR folding and membrane insertion do not exacerbate this response. CFTR translation abortion was also largely unaffected by regulators of translation kinetics such as codon usage, the ribosome collision sensor GCN1, and the SRP ER targeting complex. We propose that the RQC can be triggered by the inherent difficulties in synthesizing transmembrane segments, resulting from their inappropriate interaction with the protein synthesis machinery. Our study uncovers and characterizes a novel physiological role for the RQC in dealing with elongation-arrested transmembrane proteins.

  • Open Access

    Integrated data from R405W desmin knock-in mice highlight alterations of mitochondrial function, protein quality control, and myofibrillar structure in the initial stages of myofibrillar myopathy

    by Sabrina Batonnet-Pichon, Florence Delort, Alain Lilienbaum, Carolin Berwanger, Dorothea Schultheis, Ursula Schlötzer-Schrehardt, Andreas Schmidt, Steffen Uebe, Yosra Baiche, Tom J. Eisenack, et al.

    Background: Mutations in the desmin gene cause skeletal myopathies and cardiomyopathies. The objective of this study was to elucidate the molecular pathology induced by the expression of R405W mutant desmin in murine skeletal muscle tissue. Methods: A comprehensive characterization of the skeletal muscle pathology in hetero- and homozygous R405W desmin knock-in mice was performed, employing grip strength, blood acylcarnitine and amino acid, histological, ultrastructural, immunofluorescence, immunoblot, ribosomal stalling, RNA sequencing and proteomic analyses. Results: Both hetero- and homozygous R405W desmin knock-in mice showed classical myopathological features of a myofibrillar myopathy with desmin-positive protein aggregation, degenerative changes of the myofibrillar apparatus, increased autophagic build-up, and mitochondrial alterations. Muscle weakness and increased blood concentrations of acylcarnitines and amino acids were only present in homozygous animals. During its translation, mutant desmin does not induce terminal ribosomal stalling. Analyses of RNA sequencing and proteomic data from soleus muscle of 3-month-old mice depicted 59 up- and 2 down-regulated mRNAs and 101 up- and 18 down-regulated proteins that were shared between the heterozygous and homozygous genotypes in the respective omics datasets compared to the wild-type genotype. Combined analysis of the omics data demonstrated 187 significantly dysregulated candidates distributed across four groups of regulation. A down-regulation on the mRNA and protein levels was observed for a multitude of mitochondrial proteins including essential proton gradient-dependent carriers. Up-regulation on both omics levels was present for the transcription factor Mlf1, which is a binding partner of protein quality control related Dnajb6. Down-regulated on mRNA but up-regulated on the protein level was the sarcomeric lesion marker Xirp2 (xin actin-binding repeat-containing protein 2), whereas Ces2c (acylcarnitine hydrolase) was regulated in the opposite way. Conclusions: The present study demonstrates that the expression of mutant desmin results in a myofibrillar myopathy in hetero- and homozygous R405W desmin knock-in mice. Combined morphological, transcriptomic and proteomic analyses helped to decipher the complex pattern of early pathological changes induced by the expression of mutant desmin. Our findings highlight the importance of major mitochondrial alterations, including essential proton gradient-dependent carriers as well as Dnajb6-related protein quality control and Xin-related myofibrillar damage, in the molecular pathogenesis of desminopathies.

  • Open Access

    Ending a bad start: Triggers and mechanisms of co-translational protein degradation

    by Tom Joshua Eisenack, Débora Broch Trentini

    Proteins are versatile molecular machines that control and execute virtually all cellular processes. They are synthesized in a multilayered process requiring transfer of information from DNA to RNA and finally into polypeptide, with many opportunities for error. In addition, nascent proteins must successfully navigate a complex folding-energy landscape, in which their functional native state represents one of many possible outcomes. Consequently, newly synthesized proteins are at increased risk of misfolding and toxic aggregation. To maintain proteostasis–the state of proteome balance–cells employ a plethora of molecular chaperones that guide proteins along a productive folding pathway and quality control factors that direct misfolded species for degradation. Achieving the correct balance between folding and degradation therefore represents a fundamental task for the proteostasis network. While many chaperones act co-translationally, protein quality control is generally considered to be a post-translational process, as the majority of proteins will only achieve their final native state once translation is completed. Nevertheless, it has been observed that proteins can be ubiquitinated during synthesis. The extent and the relevance of co-translational protein degradation, as well as the underlying molecular mechanisms, remain areas of open investigation. Recent studies made seminal advances in elucidating ribosome-associated quality control processes, and how their loss of function can lead to proteostasis failure and disease. Here, we discuss current understanding of the situations leading to the marking of nascent proteins for degradation before synthesis is completed, and the emerging quality controls pathways engaged in this task in eukaryotic cells. We also highlight the methods used to study co-translational quality control.


  • Open Access

    Role for ribosome-associated quality control in sampling proteins for MHC class I-mediated antigen presentation

    by Débora Broch Trentini, Matteo Pecoraro, Shivani Tiwary, Jürgen Cox, Matthias Mann, Mark S. Hipp, F. Ulrich Hartl

    Mammalian cells present a fingerprint of their proteome to the adaptive immune system through the display of endogenous peptides on MHC-I complexes. MHC-I−bound peptides originate from protein degradation by the proteasome, suggesting that stably folded, long-lived proteins could evade monitoring. Here, we investigate the role in antigen presentation of the ribosome-associated quality control (RQC) pathway for the degradation of nascent polypeptides that are encoded by defective messenger RNAs and undergo stalling at the ribosome during translation. We find that degradation of model proteins by RQC results in efficient MHC-I presentation, independent of their intrinsic folding properties. Quantitative profiling of MHC-I peptides in wild-type and RQC-deficient cells by mass spectrometry showed that RQC substantially contributes to the composition of the immunopeptidome. Our results also identify endogenous substrates of the RQC pathway in human cells and provide insight into common principles causing ribosome stalling under physiological conditions.